Latest from Columbia University Medical Center

Kevin Kalinsky, MD, MS, highlights the recent data with alpelisib and CDK4/6 inhibitors, the toxicity differences between the 3 available CDK4/6 agents, and the next steps for both classes of agents.
Owen A. O’Connor, MD, PhD, professor of medicine and experimental therapeutics, director, Center for Lymphoid Malignancies, co-program director, Lymphoid Development and Malignancy Program, NewYork-Presbyterian/Columbia University Medical Center, shares insight on mantle cell lymphoma and T-cell lymphoma breakthroughs.
Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.
Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses central nervous system involvement in HER2-positive breast cancer.
Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the evolution of treatment for patients with HER2-positive metastatic breast cancer.
 
Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical School, discusses the potential of neratinib (Nerlynx) and tucatinib in HER2-positive metastatic breast cancer.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma. 
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma.
 
Publication Bottom Border
Border Publication
x